서브메뉴
검색
A Trioxacarcin Prodrug With Accelerated Reversion and an Enterobacteriaceae-Selective Antibiotic With Low Induction of Resistance
A Trioxacarcin Prodrug With Accelerated Reversion and an Enterobacteriaceae-Selective Antibiotic With Low Induction of Resistance
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103544
- ISBN
- 9798280717435
- DDC
- 547
- 저자명
- Valdes, Lucas C.
- 서명/저자
- A Trioxacarcin Prodrug With Accelerated Reversion and an Enterobacteriaceae-Selective Antibiotic With Low Induction of Resistance
- 발행사항
- [Sl] : Harvard University, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 399 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
- 주기사항
- Advisor: Myers, Andrew G.
- 학위논문주기
- Thesis (Ph.D.)--Harvard University, 2025.
- 초록/해제
- 요약The trioxacarcins are highly oxygenated, complex bacterial fermentation products first isolated from Streptomyces bottropensis DO-45 in 1981 with remarkable broad-spectrum antiproliferative activity against both Gram-positive bacteria and eukaryotic cells. This antiproliferative activity motivated a phase I clinical trial for LL-D49194α1, a closely related natural product, which ended with one woman dying from myocarditis and the abandonment of further development. The more recent advent of antibody-drug conjugates (ADCs), a class of targeted chemotherapeutics consisting of a monoclonal antibody conjugated to a toxic payload through a linker system, has promise for attenuating the off-target toxicity of the trioxacarcins. However, to realize a stable trioxacarcin ADC, it has been found that a prodrug of the electrophilic spiro-epoxide functionality responsible for the activity of the class is necessary. In chapters one and two of this dissertation, I detail efforts to optimize a trioxacarcin prodrug for application in an ADC by developing a simplified diversifiable pharmacophore and probing structure-activity relationships (SAR) for both antiproliferative activity and reversion kinetics. In doing so, I identify an optimized pharmacophore possessing identical potency, a three-fold increase in prodrug reversion rate, and increased hydrophilicity, as compared to previous trioxacarcin prodrug ADC warheads.Antibiotic-resistant pathogens of the Gram-negative family Enterobacteriaceae are among the deadliest of the multidrug-resistant (MDR) bacteria emerging today, taking the top two spots in the 2024 edition of the Bacterial Priority Pathogens List published by the World Health Organization. In chapters three and four, I detail the discovery and gram-scale synthesis of ciprimelpin, a potent Enterobacteriaceae-selective antibiotic that acts by inhibiting the LolCDE component of the localization of lipoproteins pathway. Unlike previously reported LolCDE inhibitors, ciprimelpin has a low propensity for resistance development: it induces a very low frequency of spontaneous resistance (FoR), and isolated mutant strains contain at least two and as many as five mutations in the target protein complex yet remain highly susceptible. Ciprimelpin is well tolerated, orally bioavailable in mice, and highly efficacious in murine infection models of MDR Enterobacteriaceae infection, either by intravenous or oral administration. Ciprimelpin's in vivo efficacy and tolerability, low propensity for resistance development, and novel mechanism of action make it a promising preclinical candidate for the treatment of infections caused by MDR-Enterobacteriaceae, including those for which there are currently no treatment options.
- 일반주제명
- Organic chemistry
- 일반주제명
- Microbiology
- 일반주제명
- Pharmacology
- 일반주제명
- Biochemistry
- 키워드
- Antibiotics
- 키워드
- Lipoproteins
- 키워드
- Trioxacarcins
- 기타저자
- Harvard University Chemistry and Chemical Biology
- 기본자료저록
- Dissertations Abstracts International. 86-12B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017357674
■00520260202103544
■006m o d
■007cr#unu||||||||
■020 ▼a9798280717435
■035 ▼a(MiAaPQ)AAI32041147
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a547
■1001 ▼aValdes, Lucas C.▼0(orcid)0009-0003-7613-5139
■24512▼aA Trioxacarcin Prodrug With Accelerated Reversion and an Enterobacteriaceae-Selective Antibiotic With Low Induction of Resistance
■260 ▼a[Sl]▼bHarvard University▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a399 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-12, Section: B.
■500 ▼aAdvisor: Myers, Andrew G.
■5021 ▼aThesis (Ph.D.)--Harvard University, 2025.
■520 ▼aThe trioxacarcins are highly oxygenated, complex bacterial fermentation products first isolated from Streptomyces bottropensis DO-45 in 1981 with remarkable broad-spectrum antiproliferative activity against both Gram-positive bacteria and eukaryotic cells. This antiproliferative activity motivated a phase I clinical trial for LL-D49194α1, a closely related natural product, which ended with one woman dying from myocarditis and the abandonment of further development. The more recent advent of antibody-drug conjugates (ADCs), a class of targeted chemotherapeutics consisting of a monoclonal antibody conjugated to a toxic payload through a linker system, has promise for attenuating the off-target toxicity of the trioxacarcins. However, to realize a stable trioxacarcin ADC, it has been found that a prodrug of the electrophilic spiro-epoxide functionality responsible for the activity of the class is necessary. In chapters one and two of this dissertation, I detail efforts to optimize a trioxacarcin prodrug for application in an ADC by developing a simplified diversifiable pharmacophore and probing structure-activity relationships (SAR) for both antiproliferative activity and reversion kinetics. In doing so, I identify an optimized pharmacophore possessing identical potency, a three-fold increase in prodrug reversion rate, and increased hydrophilicity, as compared to previous trioxacarcin prodrug ADC warheads.Antibiotic-resistant pathogens of the Gram-negative family Enterobacteriaceae are among the deadliest of the multidrug-resistant (MDR) bacteria emerging today, taking the top two spots in the 2024 edition of the Bacterial Priority Pathogens List published by the World Health Organization. In chapters three and four, I detail the discovery and gram-scale synthesis of ciprimelpin, a potent Enterobacteriaceae-selective antibiotic that acts by inhibiting the LolCDE component of the localization of lipoproteins pathway. Unlike previously reported LolCDE inhibitors, ciprimelpin has a low propensity for resistance development: it induces a very low frequency of spontaneous resistance (FoR), and isolated mutant strains contain at least two and as many as five mutations in the target protein complex yet remain highly susceptible. Ciprimelpin is well tolerated, orally bioavailable in mice, and highly efficacious in murine infection models of MDR Enterobacteriaceae infection, either by intravenous or oral administration. Ciprimelpin's in vivo efficacy and tolerability, low propensity for resistance development, and novel mechanism of action make it a promising preclinical candidate for the treatment of infections caused by MDR-Enterobacteriaceae, including those for which there are currently no treatment options.
■590 ▼aSchool code: 0084.
■650 4▼aOrganic chemistry
■650 4▼aMicrobiology
■650 4▼aPharmacology
■650 4▼aBiochemistry
■653 ▼aAntibiotics
■653 ▼aLipoproteins
■653 ▼aTrioxacarcins
■653 ▼aStreptomyces bottropensis
■653 ▼aEnterobacteriaceae
■690 ▼a0490
■690 ▼a0410
■690 ▼a0487
■690 ▼a0419
■71020▼aHarvard University▼bChemistry and Chemical Biology.
■7730 ▼tDissertations Abstracts International▼g86-12B.
■790 ▼a0084
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357674▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
